2016 Fear vs Hope: Gene Editing— Terrible turning point?
By Pete Shanks,
Deccan Chronicle
| 01. 01. 2017
The next year may represent our best chance to prevent the rise of a modern, uncontrolled and dangerously ill-considered techno-eugenics.
If new “gene editing” tools can be used to treat people who are sick, that would be a hugely welcome development. But applying them to human reproduction could all too easily open the door to a world of genetic haves and have-nots. Will it be possible for the distinction between responsible and irresponsible applications of human genetic technologies to hold, in policy and in practice? There is hope, but the signals from 2016 are very worrying.
One year ago, the U.S. National Academies Summit on Human Gene Editing ended with a consensus statement that proceeding with inheritable (germline) gene editing would be “irresponsible” until both the science was proven and there was “broad societal consensus about the appropriateness of the proposed application.”
It didn’t take long for that to seem wildly optimistic. Even before that announcement, and in complete secrecy, a rogue American scientist had defied authorities by using Mexican facilities to create a baby for a Jordanian couple using...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...